Pieris Pharmaceuticals GmbH
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Previously recorded as Pieris AG (to 2016)
5
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Mar 3, 2027
- 2 fees due Apr 3 to 6, 2027 · next Apr 3
- 1 fee due May 28, 2027The maintenance fee for Muteins of Human Lipocalin 2 (LCN2,HNGAL) with Affinity for a Given Target (US 11,827,681) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 4 fees due Jun 10 to 29, 2027 · next Jun 10
- 2 fees due Jul 7, 2027
- 1 fee due Aug 16, 2027The maintenance fee for Muteins of Human Lipocalin 2 with Affinity for GLYPICAN-3 (GPC-3) (US 9,260,492) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
- 1 fee due Sep 5, 2027The maintenance fee for Anti-Cancer Fusion Polypeptide Capable of Binding Both CD137 and GLYPICAN-3 (GPC3) (US 11,919,931) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for Muteins of Human Lipocalin 2 (LCN2,HNGAL) with Affinity for a Given Target (US 10,618,941) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,892,827 | Compound with Affinity for the Cytotoxic T Lymphocyte-Associated Antigen (CTLA-4) In force · High confidence | In force | High confidence | |
| US 9,221,887 | Muteins of Tear Lipocalin and Methods for Obtaining the Same In force · Medium confidence | In force | Medium confidence | |
| US 8,313,924 | Muteins of Tear Lipocalin and Methods for Obtaining the Same In force · High confidence | In force | High confidence | |
| US 9,549,968 | Muteins of Human Lipocalin 2 (LCNC,HNGAL) with Affinity for a Given Target In force · High confidence | In force | High confidence | |
| US 10,618,941 | Muteins of Human Lipocalin 2 (LCN2,HNGAL) with Affinity for a Given Target In force · High confidence | In force | High confidence | |
| US 8,986,951 | Tear Lipocalin in Muteins Binding IL-4 R Alpha In force · High confidence | In force | High confidence | |
| US 10,232,014 | Tear Lipocalin Muteins Binding IL-4 R Alpha In force · Low confidence | In force | Low confidence | |
| US 11,827,681 | Muteins of Human Lipocalin 2 (LCN2,HNGAL) with Affinity for a Given Target In force · High confidence | In force | High confidence | |
| US 8,987,415 | Recombinant Bacterial Lipocalin BLC and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,260,492 | Muteins of Human Lipocalin 2 with Affinity for GLYPICAN-3 (GPC-3) In force · High confidence | In force | High confidence |
Also on record, not counted in the 26: 30 lapsed for an unpaid fee · 10 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 abandoned · 4 no status recorded